Lexicon Pharmaceutcl (LXRX) Stock Price, Quote & News

Company Profile

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. The company develops sotagliflozin, an orally-delivered small molecule drug for the treatment of hypertrophic cardiomyopathy, and ZYNQUISTA (sotagliflozin) for the treatment of type 1 diabetes. It also commercializes INPEFA (sotagliflozin), a once-daily oral tablet to reduce the risk of cardiovascular death, hospit...

Industry: Biotechnology

Sector: Healthcare

Phone: 281 863 3000

Fax: 281 863 8088

Website: www.lexpharma.com

Address:

2445 Technology Forest Boulevard, 11th Floor, The Woodlands, United States

beezee8 Jul. 22 at 4:04 PM

$LXRX What's happened here?? 10 mil available?

0 · Reply

sabill Jul. 22 at 3:33 PM

$LXRX I think the 2pm to 3pm time frame today will be very telling. If this selloff continues then things could get ugly. On the other side, if it absorbs the selling and turns back even or green, that would be a strong indication that there is a demand for the stock at a bargain price. High volume for either of those possibilities would just reinforce the narrative. Could get very interesting.

1 · Reply

TheMotleyMonk Jul. 22 at 2:51 PM

$LXRX A solid report of the current status including the share price flucuation bases solely on low volume: https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-lxrx/lexicon-pharmaceuticals

0 · Reply

User123321 Jul. 22 at 2:31 PM

$LXRX They better start delivering on what Mike sexton boldly speaks of. Nothing noted on the chart and definitely trading in a channel but it’s starting to get an H and S look to it. Do what you say please Management!

1 · Reply

Jas7235355 Jul. 22 at 2:19 PM

$LXRX Excuse me mid year is July 2

1 · Reply

Dooright Jul. 22 at 2:07 PM

$LXRX Low volume shake by the crooks. Manipulation continues unabated! Our time will come very soon. Hold tight! 😜 Doc C. 🤓

1 · Reply

stefano62 Jul. 22 at 2:06 PM

$LXRX the last Hope Is that the missed news are due to silent period because of some big negotiation, even if I have serious doubts about that

1 · Reply

macrossluvsrobotech Jul. 22 at 2:04 PM

$LXRX Zynquista 💪🫡 Living with well-treated HIV can be easier than living with insulin-dependent diabetes Some doctors say that with modern HIV medication, patients can live nearly normal lifespans — and in some ways, it’s easier to manage than type 2 diabetes that requires insulin.

0 · Reply

Jas7235355 Jul. 22 at 1:53 PM

$LXRX Mid Year = July 16

1 · Reply

Hit1000X Jul. 22 at 1:29 PM

$LXRX

0 · Reply

Lexicon Pharmaceuticals Transcript: Jefferies Global Healthcare Conference 2026

Jun 3, 2026, 8:00 AM EDT - 7 weeks ago

Lexicon to Present Data at the American Diabetes Association (ADA) 2026 Scientific Sessions

May 28, 2026, 8:30 AM EDT - 7 weeks ago

Lexicon Pharmaceuticals to Present at the 2026 Jefferies Global Healthcare Conference

May 26, 2026, 7:00 AM EDT - 2 months ago

Lexicon Pharmaceuticals Slides: Investor presentation

May 19, 2026, 4:30 PM EDT - 2 months ago

Lexicon Pharmaceuticals Transcript: H.C. Wainwright 4th Annual BioConnect Investor Conference

May 12, 2026, 8:30 AM EDT - 2 months ago

Lexicon Pharmaceuticals to Present at the 4th Annual H.C. Wainwright BioConnect Investor Conference

2026-05-11T11:01:50.000Z - 2 months ago

Lexicon price target raised to $3.10 from $2.30 at Citi

May 7, 2026, 8:30 AM EDT - 2 months ago

Lexicon Pharmaceuticals Earnings Call Transcript: Q1 2026

May 7, 2026, 8:30 AM EDT - 2 months ago

Lexicon Pharmaceuticals Earnings release: Q1 2026

May 7, 2026, 8:30 AM EDT - 2 months ago

Lexicon Pharmaceuticals Slides: Q1 2026

May 7, 2026, 8:30 AM EDT - 2 months ago

Lexicon Pharmaceuticals Quarterly report: Q1 2026

May 7, 2026, 7:30 AM EDT - 2 months ago

Lexicon Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Clinical Updates

May 4, 2026, 4:05 PM EDT - 2 months ago

Lexicon Pharmaceuticals Announces $100 Million Loan Facility with Hercules Capital

HTGC

Apr 30, 2026, 8:00 AM EDT - 2 months ago

Lexicon Pharmaceuticals to Report First Quarter 2026 Financial Results on May 7, 2026

2026-04-17T12:22:28.000Z - 3 months ago

Lexicon to present data at AAN annual meeting on Progress Phase 2b study

Apr 17, 2026, 8:00 AM EDT - 3 months ago

Lexicon to Present Data at the American Academy of Neurology (AAN) Annual Meeting

Mar 24, 2026, 8:00 AM EDT - 4 months ago

Lexicon Announces Three Presentations at the American College of Cardiology (ACC) Annual Scientific Session & Expo

2026-03-23T11:46:37.000Z - 4 months ago

Lexicon, Novo Nordisk announce initiation of LX9851 study

NVO

Mar 23, 2026, 7:30 AM EDT - 4 months ago

Lexicon Pharmaceuticals and Novo Nordisk Announce initiation of Phase 1 study with oral obesity drug candidate LX9851

Mar 16, 2026, 8:00 AM EDT - 4 months ago

Lexicon Pharmaceuticals Proxy statement: Proxy Filing

Mar 16, 2026, 8:00 AM EDT - 4 months ago

Lexicon Pharmaceuticals Proxy statement: Proxy Filing

Mar 11, 2026, 10:00 AM EDT - 4 months ago

Lexicon Pharmaceuticals Transcript: Leerink Global Healthcare Conference 2026

2026-03-11T12:17:17.000Z - 4 months ago

Lexicon announces results from post hoc analysis on data of sotagliflozin

Mar 11, 2026, 8:00 AM EDT - 4 months ago

Lexicon to Present Data on Effect of Kidney Function on the Long-term Efficacy and Safety of Sotagliflozin in Patients with Type 1 Diabetes at 19th International Conference on Advanced Technologies & Treatments for Diabetes

2026-03-10T10:53:36.000Z - 4 months ago

Lexicon price target raised to $2.30 from $2.10 at Citi

2026-03-05T16:06:30.000Z - 4 months ago

Lexicon price target raised to $6 from $4 at H.C. Wainwright

Mar 5, 2026, 8:30 AM EST - 4 months ago

Lexicon Pharmaceuticals Earnings Call Transcript: Q4 2025

Mar 5, 2026, 8:30 AM EST - 4 months ago

Lexicon Pharmaceuticals Annual report: Q4 2025

Mar 5, 2026, 8:30 AM EST - 4 months ago

Lexicon Pharmaceuticals Earnings release: Q4 2025

Mar 5, 2026, 8:30 AM EST - 4 months ago

Lexicon Pharmaceuticals Slides: Q4 2025

2026-03-05T12:08:49.000Z - 4 months ago

Lexicon reports Q4 EPS (4c), consensus (7c)

Mar 5, 2026, 6:59 AM EST - 4 months ago

Lexicon Pharmaceuticals Reports Fourth Quarter 2025 Financial Results and Provides Clinical Updates

Mar 3, 2026, 4:01 PM EST - 5 months ago

Lexicon Pharmaceuticals to Participate in Three Upcoming March Investor Conferences

Feb 26, 2026, 8:30 AM EST - 5 months ago

Lexicon Pharmaceuticals to Report Fourth Quarter 2025 Financial Results on March 5, 2026

Feb 17, 2026, 7:00 AM EST - 5 months ago

Lexicon Pharmaceuticals Proxy statement: Proxy Filing

Feb 6, 2026, 5:17 PM EST - 5 months ago

Lexicon Announces Closing of Approximately $94.6 Million Public Offering and Concurrent Private Placement

Jan 30, 2026, 2:50 AM EST - 6 months ago

Lexicon Announces Pricing of Approximately $94.6 Million Public Offering and Concurrent Private Placement

2026-01-29T21:36:16.000Z - 6 months ago

Lexicon announces common stock offering, no amount given

Jan 29, 2026, 4:31 PM EST - 6 months ago

Lexicon Announces Proposed Public Offering of Common Stock

Jan 23, 2026, 8:30 AM EST - 6 months ago

Lexicon Pharmaceuticals to Ring the Nasdaq Closing Bell on January 27, 2026 to Celebrate 30th Anniversary

2026-01-21T13:42:01.000Z - 6 months ago

Lexicon completes End-of-Phase 2 meeting with U.S. FDA for pilavapadin

Jan 21, 2026, 8:30 AM EST - 6 months ago

Lexicon Pharmaceuticals Announces Successful End-of-Phase 2 Meeting with FDA For Pilavapadin in the Treatment of Diabetic Peripheral Neuropathic Pain

Jan 20, 2026, 6:59 AM EST - 6 months ago

Viatris Expands Innovative Portfolio in Cardiovascular Diseases with the Company's First Launch of Inpefa® (Sotagliflozin) for the Treatment of Heart Failure

VTRS

Jan 15, 2026, 3:00 PM EST - 6 months ago

Lexicon Pharmaceuticals Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 15, 2026, 3:00 PM EST - 6 months ago

Lexicon Pharmaceuticals Slides: 44th Annual J.P. Morgan Healthcare Conference

2026-01-14T10:45:10.000Z - 6 months ago

Lexicon price target raised to $2.10 from $1.90 at Citi

2026-01-12T12:55:44.000Z - 6 months ago

Lexicon sees cash runway into 2027

Jan 12, 2026, 7:30 AM EST - 6 months ago

Lexicon Pharmaceuticals Provides a Business and Pipeline Update at the 44th Annual J.P. Morgan Healthcare Conference

2026-01-09T13:40:14.000Z - 6 months ago

Lexicon publishes White Paper on treatments for chronic pain

Jan 9, 2026, 8:30 AM EST - 6 months ago

Lexicon Pharmaceuticals Publishes “Relief is Possible: Ensuring Access to Effective Treatments for Chronic Pain”

Jan 7, 2026, 8:30 AM EST - 7 months ago

Lexicon Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference

2025-12-10T13:40:17.000Z - 8 months ago

Lexicon announces publication of preclinical data on ACSL5

NVO

Dec 10, 2025, 8:30 AM EST - 8 months ago

Lexicon Pharmaceuticals Announces Publication of Preclinical Data in the Journal of the Endocrine Society on Acyl-CoA Synthetase 5 (ACSL5) Reinforcing the Scientific Rationale for LX9851

Dec 5, 2025, 8:30 AM EST - 8 months ago

Clinical Data on Effect of Sotagliflozin on Adipose Distribution in Non-Diabetic Patients will be Presented at the 2025 Cardio Vascular Clinical Trialists Forum

Dec 4, 2025, 9:10 AM EST - 8 months ago

Lexicon Pharmaceuticals Transcript: Evercore ISI 8th Annual HealthCONx Conference

Dec 3, 2025, 9:00 AM EST - 8 months ago

Lexicon Pharmaceuticals Transcript: Piper Sandler 37th Annual Healthcare Conference

Nov 25, 2025, 8:30 AM EST - 8 months ago

Lexicon Pharmaceuticals to Participate in Two Upcoming December Investor Conferences

Nov 18, 2025, 12:00 PM EST - 8 months ago

Lexicon Pharmaceuticals Transcript: Jefferies London Healthcare Conference 2025

Nov 14, 2025, 7:00 AM EST - 8 months ago

Lexicon Pharmaceuticals Slides: Corporate presentation

Nov 11, 2025, 8:30 AM EST - 9 months ago

Lexicon Pharmaceuticals to Participate at the Jefferies 2025 London Healthcare Conference

2025-11-09T18:20:08.000Z - 9 months ago

Lexicon announces new sotagliflozin clinical data at AHA Sessions 2025

Nov 8, 2025, 2:30 PM EST - 9 months ago

Clinical Data Demonstrating Efficacy of Sotagliflozin in Preserved Ejection Fraction Heart Failure (HFpEF) without Diabetes Presented at American Heart Association (AHA) Annual Scientific Sessions 2025

Nov 6, 2025, 8:30 AM EST - 9 months ago

Lexicon Pharmaceuticals Earnings Call Transcript: Q3 2025

Nov 6, 2025, 8:30 AM EST - 9 months ago

Lexicon Pharmaceuticals Quarterly report: Q3 2025

Nov 6, 2025, 8:30 AM EST - 9 months ago

Lexicon Pharmaceuticals Earnings release: Q3 2025

Nov 6, 2025, 8:30 AM EST - 9 months ago

Lexicon Pharmaceuticals Slides: Q3 2025

2025-11-06T12:41:13.000Z - 9 months ago

Lexicon reports Q3 EPS (4c), consensus (7c)

Nov 6, 2025, 7:30 AM EST - 9 months ago

Lexicon Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides R&D Updates

Nov 4, 2025, 8:30 AM EST - 9 months ago

Data Demonstrating Unique Benefits of Sotagliflozin in Diverse Patient Populations will be Presented at the Hypertrophic Cardiomyopathy Society and American Heart Association's Sessions 2025 in New Orleans

Oct 30, 2025, 8:30 AM EDT - 9 months ago

Lexicon Pharmaceuticals to Report Third Quarter 2025 Financial Results on November 6, 2025

Oct 14, 2025, 8:00 AM EDT - 10 months ago

Lexicon Pharmaceuticals Presents Additional Pilavapadin Data in Diabetic Peripheral Neuropathic Pain at 19th Annual Pain Therapeutics Summit

Oct 8, 2025, 7:59 AM EDT - 10 months ago

Lexicon Pharmaceuticals Convenes Roundtable to Address Public Policy Gaps for People with Chronic Pain

Sep 22, 2025, 4:00 PM EDT - 10 months ago

Lexicon Pharmaceuticals Announces Update on Submission of Additional Data to U.S. FDA Supporting the Benefit-Risk Profile of Zynquista® in Type 1 Diabetes

Sep 17, 2025, 7:00 AM EDT - 11 months ago

Pilavapadin Provides Meaningful Pain Reduction in Adults with Diabetic Peripheral Neuropathic Pain (DPNP) in Data Presented at the European Association for the Study of Diabetes (EASD) and NEUROdiab Annual Meetings

Sep 11, 2025, 8:30 AM EDT - 11 months ago

Lexicon Pharmaceuticals to Present Additional Clinical Data on Pilavapadin at Three Upcoming Medical Meetings

Sep 8, 2025, 2:30 PM EDT - 11 months ago

Lexicon Pharmaceuticals Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Sep 8, 2025, 8:30 AM EDT - 11 months ago

Lexicon Pharmaceuticals Announces Submission of Additional Data to U.S. FDA Supporting the Benefit-Risk Profile of Zynquista® in Type 1 Diabetes

Sep 4, 2025, 8:30 AM EDT - 11 months ago

Lexicon Pharmaceuticals to Present New Preclinical Data on Pilavapadin in Chemotherapy-Induced Pain and Multiple Sclerosis Pain at NeuPSIG 2025

Sep 3, 2025, 1:45 PM EDT - 11 months ago

Lexicon Pharmaceuticals Transcript: Citi's Biopharma Back to School Conference

Sep 3, 2025, 8:30 AM EDT - 11 months ago

Lexicon Pharmaceuticals Announces Presentation of Diabetic Peripheral Neuropathic Pain Patient Insights at PAINWeek 2025

Sep 2, 2025, 8:30 AM EDT - 11 months ago

Sotagliflozin Provides Consistent Relative Risk Reduction in Heart Failure and Major Cardiovascular Events Across All Age Ranges, Including Greater Than 75, in Data Presented at the European Society of Cardiology (ESC) 2025 Congress

Aug 27, 2025, 8:30 AM EDT - 11 months ago

Lexicon Pharmaceuticals to Participate at Two Upcoming Investor Conferences

Aug 6, 2025, 8:30 AM EDT - 1 year ago

Lexicon Pharmaceuticals Earnings Call Transcript: Q2 2025

Aug 6, 2025, 8:30 AM EDT - 1 year ago

Lexicon Pharmaceuticals Quarterly report: Q2 2025

Aug 6, 2025, 8:30 AM EDT - 1 year ago

Lexicon Pharmaceuticals Earnings release: Q2 2025

Aug 6, 2025, 8:30 AM EDT - 1 year ago

Lexicon Pharmaceuticals Slides: Q2 2025

Aug 6, 2025, 7:30 AM EDT - 1 year ago

Lexicon Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Updates

Jul 31, 2025, 8:00 AM EDT - 1 year ago

Lexicon Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Requirement

Jul 23, 2025, 8:00 AM EDT - 1 year ago

Lexicon Pharmaceuticals to Report Second Quarter 2025 Financial Results on August 6, 2025

Jul 18, 2025, 8:00 AM EDT - 1 year ago

Lexicon to Present Patient-reported Data on Diabetic Peripheral Neuropathic Pain (DPNP) at the 7th Annual Meeting of the American Society of Pain and Neuroscience (ASPN 2025)

Jun 25, 2025, 7:00 AM EDT - 1 year ago

Lexicon Pharmaceuticals Slides: Corporate Presentation

Jun 23, 2025, 8:00 AM EDT - 1 year ago

Data Demonstrating Sotagliflozin Reduces the Risk of Clinically Important Hypoglycemic Events in Adults with Type 1 Diabetes When Added to Insulin Presented at the 85th Scientific Sessions of the American Diabetes Association (ADA)

Jun 18, 2025, 8:30 AM EDT - 1 year ago

Lexicon to Present Data at the 85th Scientific Sessions of the American Diabetes Association (ADA)

Jun 5, 2025, 12:50 PM EDT - 1 year ago

Lexicon Pharmaceuticals Transcript: Jefferies Global Healthcare Conference 2025

May 29, 2025, 8:00 AM EDT - 1 year ago

Lexicon Pharmaceuticals to Present at the 2025 Jefferies Global Healthcare Conference

May 20, 2025, 9:30 AM EDT - 1 year ago

Lexicon Pharmaceuticals Transcript: H.C. Wainwright 3rd Annual BioConnect Investor Conference 2025

May 19, 2025, 8:00 AM EDT - 1 year ago

SONATA-HCM Study Design Presented at Heart Failure 2025, the Annual Congress of the Heart Failure Association of the European Society of Cardiology

May 13, 2025, 5:00 PM EDT - 1 year ago

Lexicon Pharmaceuticals Earnings Call Transcript: Q1 2025

May 13, 2025, 5:00 PM EDT - 1 year ago

Lexicon Pharmaceuticals Quarterly report: Q1 2025

May 13, 2025, 5:00 PM EDT - 1 year ago

Lexicon Pharmaceuticals Earnings release: Q1 2025

May 13, 2025, 5:00 PM EDT - 1 year ago

Lexicon Pharmaceuticals Slides: Q1 2025

May 13, 2025, 4:00 PM EDT - 1 year ago

Lexicon Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Updates

May 6, 2025, 4:30 PM EDT - 1 year ago

Lexicon Pharmaceuticals to Present at the 3rd Annual H.C. Wainwright BioConnect Investor Conference

beezee8 Jul. 22 at 4:04 PM

$LXRX What's happened here?? 10 mil available?

0 · Reply

sabill Jul. 22 at 3:33 PM

1 · Reply

TheMotleyMonk Jul. 22 at 2:51 PM

$LXRX A solid report of the current status including the share price flucuation bases solely on low volume: https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-lxrx/lexicon-pharmaceuticals

0 · Reply

User123321 Jul. 22 at 2:31 PM

1 · Reply

Jas7235355 Jul. 22 at 2:19 PM

$LXRX Excuse me mid year is July 2

1 · Reply

Dooright Jul. 22 at 2:07 PM

$LXRX Low volume shake by the crooks. Manipulation continues unabated! Our time will come very soon. Hold tight! 😜 Doc C. 🤓

1 · Reply

stefano62 Jul. 22 at 2:06 PM

$LXRX the last Hope Is that the missed news are due to silent period because of some big negotiation, even if I have serious doubts about that

1 · Reply

macrossluvsrobotech Jul. 22 at 2:04 PM

0 · Reply

Jas7235355 Jul. 22 at 1:53 PM

$LXRX Mid Year = July 16

1 · Reply

Hit1000X Jul. 22 at 1:29 PM

$LXRX

0 · Reply

CatchTheCleanUpSet Jul. 22 at 12:22 PM

$LXRX June 4th Jeffries conference at 3:00 min. The Steno1 data is "...well in line with what our expectation is for a successful resubmission..." for the Zynquista NDA which is expected to be "mid-year".

3 · Reply

gucag006 Jul. 22 at 1:38 AM

$LXRX Still watching hairs grow on rock. Quite a few overdue items: 1. Zynquista-T1D NDA resubmission 2. Inpefa-HCM P3 enrollment completion 3. Pilavapadin Partnership or go-it-alone 4. Pilavapadin-DPNP P3 trial readiness and initiation 5. LX9851 P1 enrollment completion Dead silence, instead! The closer to the next ER date of early August, the more nervous I am fearing of bad news. Under Coats we got nothing but bad news one after another, I really hope ME starts to bring in good ones, but so far he only has the Novo-partnership under his belt. GLTA!

1 · Reply

gucag006 Jul. 21 at 10:00 PM

$LXRX Its a matter of attitude and comfort zone at Lexi! CORT, my other biotech holding, got the CRL at the end of 2025, they had a type-D meeting with NDA, announced plan to resubmit in mid May, and actually resubmitted in June. Its stock not only fully recovered, but shut up to new heights (with a 2nd ovarian cancer drug approved adding to the mix). Lexi's team only has to deal with RD, who paid them good salaries. They just don't have the fire in their eyes getting things done. I thought ME steps in to change the culture - apparently not good enough! Lexi has similar or more ST to LT catalysts as CORT, and their SP trajectories should be similar, but not. The difference is attitude and comfort zone. Frustrating to say the least! Still a believer in Sota/LX9211/LX985, with patience running out though!

1 · Reply

MYFLAUT Jul. 21 at 9:14 PM

$LXRX

0 · Reply

gucag006 Jul. 21 at 9:12 PM

$LXRX Well, the one and only one investor matters to them - you know whom!

1 · Reply

Hatrak1 Jul. 21 at 9:00 PM

$LXRX You wouldn't understand why your balls were itching if you were picking fleas out of your crotch ! 😆

0 · Reply

Hatrak1 Jul. 21 at 8:59 PM

$LXRX Yep ! 👍

0 · Reply

MYFLAUT Jul. 21 at 8:56 PM

$LXRX

0 · Reply

liloleme4 Jul. 21 at 7:55 PM

$LXRX Closing nicely Lexi! Wonder who wants in and what they might be expecting soon...

0 · Reply

beezee8 Jul. 21 at 7:52 PM

$LXRX Inverse H&S? I see why burner boy is worried

1 · Reply

learningntrading Jul. 21 at 7:22 PM

$LXRX At least give us few words update - waiting for steno result, safety profile not met, filed already, partnership talk in-progress, buyout talk in progress, you are totally f..ked up; anything please....

2 · Reply

atreus57 Jul. 21 at 7:12 PM

$LXRX stick with lexicon, I did it and made good money 💰

0 · Reply

Market Cap	1.03B
Revenue (ttm)	49.80M
Net Income (ttm)	-50.34M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-101.08%
Debt to Equity Ratio	0.24

Volume	2,348,300
Avg Vol	3,654,098
Day's Range	N/A - N/A
Shares Out	444.20M
Stochastic %K	89%
Beta	1.05
Analysts	Strong Sell
Price Target	$3.77